

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

**REVISION TO ANNUAL CAP OF CONTINUING CONNECTED
TRANSACTIONS**

Reference is made to the disclosure in relation to the Testing Service Framework Agreement in the Prospectus.

Due to the anticipated increase in WuXi Biologics Group's demand for our testing service arising from its business expansion, the Board resolved to adjust the Original Annual Cap of the Testing Service Framework Agreement for the financial year ending December 31, 2020.

As at the date of this announcement, the Founding Individuals, who are the Directors, are the controlling shareholders of WuXi Biologics. Accordingly, WuXi Biologics is regarded as an associate of the Founding Individuals and hence the connected person of the Company under the Listing Rules. Therefore, the Testing Service Framework Agreement and the transactions contemplated thereunder constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As the highest applicable percentage ratio (as defined under Rule 14.07 of the Listing Rules) in respect of the New Annual Cap of the Testing Service Framework Agreement for the year ending December 31, 2020 exceeds 0.1% but is less than 5%, the transactions contemplated thereunder are subject to the announcement and annual reporting requirements under Chapter 14A of the Listing Rules, but are exempt from the circular (including independent financial advice) and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

REVISION TO ORIGINAL ANNUAL CAP

Reference is made to the disclosure in relation to the Testing Service Framework Agreement in the Prospectus. As of the date of this announcement, the Original Annual Cap has not been exceeded.

Due to the anticipated increase in WuXi Biologics Group's demand for our testing service arising from its business expansion, on March 24, 2020, the Board resolved to adjust the annual cap for the Testing Service Framework Agreement for the year ending December 31, 2020 from the Original Annual Cap of RMB31.1 million to the New Annual Cap of RMB51.0 million.

The New Annual Cap was estimated based on (i) the historical transaction amounts paid by WuXi Biologics Group to our Group for the testing services in the previous two years; (ii) the transaction amounts under the Testing Service Framework Agreement incurred so far in 2020; and (iii) the increasing demand of WuXi Biologics Group for testing services.

Save for the revision of the Original Annual Cap to the New Annual Cap, all the other terms of the Testing Service Framework Agreement remain unchanged. The testing service fee charged by the Group will continue to be determined with reference to the nature and value of the relevant testing services as with its other customers.

REASONS FOR AND BENEFIT OF THE NEW ANNUAL CAP

As disclosed in the Prospectus, the Group is among a handful of laboratories which possesses the technical skills to perform such testing service. The Directors believe it is in the Group's ordinary course of business to provide services to Wuxi Biologics Group as if to its other customers.

Taking into account the bases set out above, the Board envisages that the Original Annual Cap for the year ending December 31, 2020 would be exceeded and therefore resolved to revise the annual cap. The Directors (including the independent non-executive Directors) are of the view that the Testing Service Framework Agreement has been conducted and will continue to be conducted on arm's length basis and on normal commercial terms in the ordinary and usual course of business of the Company and that the terms of the Testing Service Framework Agreement and the New Annual Cap are fair and reasonable and the Testing Service Framework Agreement is in the interest of the Company and its Shareholders as a whole.

INFORMATION ON THE GROUP AND WUXI BIOLOGICS GROUP

The Group

The Group is primarily engaged in providing comprehensive and integrated research and manufacturing services throughout the discovery, development and manufacturing spectrum for small molecule drugs. It also provides development and manufacturing services for cell therapies and gene therapies as well as providing testing services for medical devices.

WuXi Biologics Group

WuXi Biologics (Cayman) Inc. (藥明生物技術有限公司) is a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on The Stock Exchange of Hong Kong Limited (Stock code: 2269). WuXi Biologics Group is principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry in both the PRC and other overseas countries. It is regarded as an associate of the Founding Individuals and hence a connected person of the Group.

LISTING RULES IMPLICATIONS

According to Rule 14A.54 of the Listing Rules, if the Company proposes to revise the annual caps for continuing connected transactions, the Company will be required to re-comply with the provisions of Chapter 14A of the Listing Rules in relation to the relevant connected transaction. As at the date of this announcement, the Founding Individuals, who are the Directors of the Company, are the controlling shareholders of WuXi Biologics. Accordingly, WuXi Biologics is regarded as an associate of the Founding Individuals and hence the connected person of the Company under the Listing Rules. Therefore, the Testing Service Framework Agreement and the transactions contemplated thereunder constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As the highest applicable percentage ratio (as defined under Rule 14.07 of the Listing Rules) in respect of the New Annual Cap of the Testing Service Framework Agreement for the year ending December 31, 2020 exceeds 0.1% but is less than 5%, the transactions contemplated thereunder are subject to the announcement and annual reporting requirements under Chapter 14A of the Listing Rules, but are exempt from the circular (including independent financial advice) and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

As at the date of this announcement, the Founding Individuals, by virtue of being the controlling shareholders of WuXi Biologics, and Mr. Edward Hu and Dr. Yibing Wu, by virtue of being directors of WuXi Biologics, have material interests in the Testing Service Framework Agreement and the transactions thereunder, and have abstained from voting on the Board resolutions approving the New Annual Cap.

Save as disclosed above, none of the Directors has a material interest in the Testing Service Framework Agreement, the transactions contemplated thereunder, or is otherwise required to abstain from voting on the Board resolutions approving the New Annual Cap.

The Company will continue to monitor its transactions with its connected persons, including but not limited to, WuXi Biologics Group, and ensure all connected transactions are conducted in compliance with Chapter 14A of the Listing Rules and make timely announcement if and when disclosure obligations thereunder arises.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions have the following meanings:

“Board”	the board of directors of the Company
“Company”	WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司), a joint stock limited company incorporated under the laws of the PRC
“connected person”	has the meaning ascribed to it in the Listing Rules
“Directors”	the directors of the Company
“Founding Individuals”	Dr. Ge Li, Dr. Ning Zhao, Mr. Xiaozhong Liu and Mr. Zhaohui Zhang
“Group”	the Company and its subsidiaries from time to time
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on the Main Board of The Stock Exchange of Hong Kong Limited
“New Annual Cap”	the revised annual cap in respect of the amounts paid or payable by WuXi Biologics Group under the Testing Service Framework Agreement for the financial year ending December 31, 2020, being RMB51.0 million

“Original Annual Cap”	the annual cap in respect of the amounts paid or payable by WuXi Biologics Group under the Testing Service Framework Agreement for the financial year ending December 31, 2020 as disclosed in the Prospectus
“PRC”	the People’s Republic of China, which for the purpose of this announcement only, excludes Hong Kong, the Macau Special Administrative Region and Taiwan
“Prospectus”	the prospectus issued by the Company dated December 3, 2018 in relation to the listing of the shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited on December 13, 2018
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	holder(s) of the shares of the Company
“Testing Service Framework Agreement”	the testing service framework agreement dated May 17, 2017 and a supplementary agreement thereto dated November 23, 2018, entered into between the Company and WuXi Biologics pursuant to which the Company agreed to provide certain testing services to WuXi Biologics Group as disclosed in the Prospectus
“WuXi Biologics”	WuXi Biologics (Cayman) Inc. (藥明生物技術有限公司) (stock code: 2269), a company incorporated under the laws of Cayman Islands with limited liability on February 27, 2014, the shares of which are listed on the Main Board of the Stock Exchange since June 13, 2017
“WuXi Biologics Group”	WuXi Biologics and its subsidiaries from time to time
“%”	per cent

By order of the Board
WuXi AppTec Co., Ltd.
Dr. Ge Li
Chairman

Hong Kong, March 24, 2020

As of the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purpose only*